ReviewCardiovascular endocrinology & metabolism2025
How does the addition of antiplatelet therapy to antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease affect outcomes? A meta-analysis of randomized controlled trials.
Review in Cardiovascular endocrinology & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) and stable coronary artery disease (CAD) often coexist, creating a significant burden. The efficacy of adding antiplatelet therapy to oral anticoagulant (OAC) therapy in treating these patients remains unclear, prompting this meta-analysis. A comprehensive search across databases was conducted for relevant studies. Outcomes of interest included net adverse clinical event (NACE), all-cause mortality, cardiovascular disease (CVD) mortality, major bleeding, any bleeding, hemorrhagic stroke, and ischemic stroke. A hazard ratio (HR) with 95% confidence intervals (CI) was pooled. Three randomized controlled trials (3945 patients) were analyzed. OAC monotherapy (MT) significantly reduced major bleeding (HR: 0.57; 95% CI: 0.40-0.83;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.